Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Y-mAbs Therapeutics stock

YMAB
US9842411095
A2N5R0

Price

5.69
Today +/-
-0.03
Today %
-0.53 %

Y-mAbs Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Y-mAbs Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Y-mAbs Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Y-mAbs Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Y-mAbs Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Y-mAbs Therapeutics Stock Price History

DateY-mAbs Therapeutics Price
2/23/20255.69 undefined
2/20/20255.72 undefined
2/19/20256.04 undefined
2/18/20256.42 undefined
2/17/20256.20 undefined
2/13/20256.24 undefined
2/12/20256.17 undefined
2/11/20255.93 undefined
2/10/20255.77 undefined
2/9/20256.15 undefined
2/6/20256.03 undefined
2/5/20256.17 undefined
2/4/20256.21 undefined
2/3/20256.00 undefined
2/2/20255.80 undefined
1/30/20255.97 undefined
1/29/20256.19 undefined
1/28/20256.15 undefined
1/27/20256.09 undefined

Y-mAbs Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Y-mAbs Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Y-mAbs Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Y-mAbs Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Y-mAbs Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Y-mAbs Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Y-mAbs Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Y-mAbs Therapeutics’s growth potential.

Y-mAbs Therapeutics Revenue, EBIT and net profit per share

DateY-mAbs Therapeutics RevenueY-mAbs Therapeutics EBITY-mAbs Therapeutics Net Income
2030e234.76 M undefined0 undefined-14.01 M undefined
2029e173.93 M undefined-63.78 M undefined-39.14 M undefined
2028e147.29 M undefined-63.94 M undefined-41.69 M undefined
2027e130.34 M undefined-57.05 M undefined-37.28 M undefined
2026e116.25 M undefined-36.81 M undefined-36.48 M undefined
2025e106.63 M undefined-30.63 M undefined-28.37 M undefined
2024e90.25 M undefined-30.96 M undefined-28.27 M undefined
202384.82 M undefined-21.19 M undefined-21.43 M undefined
202265.27 M undefined-94.81 M undefined-95.57 M undefined
202134.9 M undefined-115.43 M undefined-55.28 M undefined
202020.75 M undefined-119.94 M undefined-119.34 M undefined
20190 undefined-83 M undefined-81.03 M undefined
20180 undefined-43.23 M undefined-43.27 M undefined
20170 undefined-19.24 M undefined-19.16 M undefined
20160 undefined-17.04 M undefined-17.06 M undefined

Y-mAbs Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00002034658490106116130147173234
-----70.0091.1829.237.1417.789.4312.0713.0817.6935.26
----365.0094.1287.6986.9081.1168.8762.9356.1549.6642.2031.20
000003257730000000
-17-19-43-81-119-55-95-21-28-28-36-37-41-39-14
-11.76126.3288.3746.91-53.7872.73-77.8933.33-28.572.7810.81-4.88-64.10
32.6332.6328.7735.1840.1243.1843.743.650000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Y-mAbs Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Y-mAbs Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
16.990.5147.8207.1114.6181.6105.878.64
000007.712.522.45
00000000
000005.56.75.07
0.40.93.74.87.77.55.54.96
17.391.4151.5211.9122.3202.3130.5111.11
000.246.45.72.31.64
00000000
00000000
000001.732.63
00000000
00.80.20.43.33.25.712.49
00.80.44.49.710.61116.76
17.392.2151.9216.3132212.9141.5127.87
               
00000004
34.4123.9225.4364.7391.6519.2543.9558
-22.4-41.6-84.8-165.9-285.2-340.5-436-457.47
0-0.200.1-0.51.41.30.45
00000000
1282.1140.6198.9105.9180.1109.2100.98
2.25.95.98.59.413.614.26.06
0.723.35.110.214.314.114.07
00000000
00000000
00000000
2.97.99.213.619.627.928.320.13
00000000
00000000
2.22.12.33.96.74.846.76
2.22.12.33.96.74.846.76
5.11011.517.526.332.732.326.88
17.192.1152.1216.4132.2212.8141.5127.87
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Y-mAbs Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Y-mAbs Therapeutics's financial health and stability.

Assets

Y-mAbs Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Y-mAbs Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Y-mAbs Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Y-mAbs Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-17-19-43-81-119-55-95-21
00000000
00000000
32023-7-10-19
214940-215427
00000000
00000000
-11-15-41-73-91-102-75-27
000-10000
000-1-26100
0000-26200
00000000
00000000
188999134210800
188998134210800
---1.00-----
00000000
7735759-9266-75-27
-11.17-15.87-41.46-75.47-91.41-103.53-75.92-27.23
00000000

Y-mAbs Therapeutics stock margins

The Y-mAbs Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Y-mAbs Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Y-mAbs Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Y-mAbs Therapeutics's sales revenue. A higher gross margin percentage indicates that the Y-mAbs Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Y-mAbs Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Y-mAbs Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Y-mAbs Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Y-mAbs Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Y-mAbs Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Y-mAbs Therapeutics Margin History

Y-mAbs Therapeutics Gross marginY-mAbs Therapeutics Profit marginY-mAbs Therapeutics EBIT marginY-mAbs Therapeutics Profit margin
2030e86.6 %0 %-5.97 %
2029e86.6 %-36.67 %-22.5 %
2028e86.6 %-43.41 %-28.3 %
2027e86.6 %-43.77 %-28.6 %
2026e86.6 %-31.66 %-31.38 %
2025e86.6 %-28.73 %-26.61 %
2024e86.6 %-34.3 %-31.33 %
202386.6 %-24.98 %-25.26 %
202288.56 %-145.26 %-146.42 %
202193.38 %-330.74 %-158.4 %
202086.6 %-578.02 %-575.13 %
201986.6 %0 %0 %
201886.6 %0 %0 %
201786.6 %0 %0 %
201686.6 %0 %0 %

Y-mAbs Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Y-mAbs Therapeutics earnings per share therefore indicates how much revenue Y-mAbs Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Y-mAbs Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Y-mAbs Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Y-mAbs Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Y-mAbs Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Y-mAbs Therapeutics Revenue, EBIT and net profit per share

DateY-mAbs Therapeutics Sales per ShareY-mAbs Therapeutics EBIT per shareY-mAbs Therapeutics Earnings per Share
2030e5.24 undefined0 undefined-0.31 undefined
2029e3.88 undefined0 undefined-0.87 undefined
2028e3.29 undefined0 undefined-0.93 undefined
2027e2.91 undefined0 undefined-0.83 undefined
2026e2.6 undefined0 undefined-0.81 undefined
2025e2.38 undefined0 undefined-0.63 undefined
2024e2.02 undefined0 undefined-0.63 undefined
20231.94 undefined-0.49 undefined-0.49 undefined
20221.49 undefined-2.17 undefined-2.19 undefined
20210.81 undefined-2.67 undefined-1.28 undefined
20200.52 undefined-2.99 undefined-2.97 undefined
20190 undefined-2.36 undefined-2.3 undefined
20180 undefined-1.5 undefined-1.5 undefined
20170 undefined-0.59 undefined-0.59 undefined
20160 undefined-0.52 undefined-0.52 undefined

Y-mAbs Therapeutics business model

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of cancer. The company was founded in 2015 and is headquartered in New York City, USA. Y-mAbs was founded by an experienced team of scientists and decision-makers with the goal of creating innovative cancer treatments to improve patients' lives and increase their survival rate. The business model of Y-mAbs is based on the discovery and development of antibodies that target and combat specific cancer cells. Through the use of cutting-edge technologies and advanced research methods, the company has made outstanding progress in cancer therapy. Y-mAbs focuses on precision and personalized medicine to develop innovative therapies tailored to the individual needs of cancer patients. Y-mAbs has several divisions in cancer treatment, including the discovery of novel cancer drugs. The company focuses on the identification of new tumor antigens that could serve as target molecules for the development of immunotherapeutic drugs. Y-mAbs aims to develop personalized and targeted cancer therapies that can identify specific tumor types and genetic mutations. Y-mAbs' portfolio includes a variety of products, including monoclonal antibodies and radioisotope-based drugs for the treatment of metastatic cancer. The company has particularly developed a novel antibody called naxitamab (Danyelza), which is approved for the treatment of neuroblastoma, a rare cancer in children. Naxitamab has been approved by the FDA as a therapeutic option for children with relapsed high-risk neuroblastoma. Y-mAbs has also established a partnership with the University of Texas MD Anderson Cancer Center to advance the development of immunotherapy in cancer treatment. Y-mAbs is also active in the research and development of radioimmunotherapy. The company has developed a radiotherapy platform called omburtamab (Tenodbulin) that specifically targets the glycosylated surface antigen B7-H3. It treats brain cancer and shows promising results. In 2019, the company also completed a groundbreaking Phase 2 study testing a new monoclonal antibody for the treatment of HER2-positive breast cancer. This study demonstrated that the combination of Y-mAbs' monoclonal antibodies with standard drugs showed a higher response in breast cancer patients, leading to potential new treatment options for breast cancer patients. In summary, Y-mAbs Therapeutics, Inc. is an advanced, innovative, and dynamic company focused on the development of personalized cancer therapies. The company strives to improve cancer treatments and extend and enhance the lives of cancer patients through its outstanding research and development. Y-mAbs' products provide a promising option for patients in advanced stages of cancer treatment, hoping for high survival rates. Y-mAbs will continue to invest in the research and development of novel cancer treatments to further improve clinical outcomes. Y-mAbs Therapeutics is one of the most popular companies on Eulerpool.com.

Y-mAbs Therapeutics SWOT Analysis

Strengths

Y-mAbs Therapeutics, Inc possesses several strengths that contribute to its competitive advantage in the pharmaceutical industry:

Y-mAbs Therapeutics offers a wide range of innovative and targeted therapeutics, focusing on developing novel antibody-based drugs to treat various types of cancer. This diverse product portfolio enables the company to address different cancer indications, increasing its potential market share.

The company's commitment to rigorous research and development activities allows Y-mAbs Therapeutics to stay at the forefront of cancer treatment advancements. By continuously advancing their scientific knowledge, the company can develop groundbreaking drugs with higher efficacy and fewer side effects.

Weaknesses

Despite its strengths, Y-mAbs Therapeutics also faces certain weaknesses that may hinder its growth and success:

Y-mAbs Therapeutics operates within a highly competitive industry, making it challenging to penetrate new markets. The company's limited market reach may pose difficulties in expanding its customer base and maximizing revenue potential.

Y-mAbs Therapeutics heavily relies on strategic partnerships for various aspects of drug development, including clinical trials, manufacturing, and distribution. A dependency on external collaborations exposes the company to potential risks and delays, impacting its ability to control critical stages of the product life cycle.

Opportunities

Y-mAbs Therapeutics has several opportunities to capitalize on and drive future growth:

With cancer rates continuing to rise globally, Y-mAbs Therapeutics can benefit from the growing need for advanced cancer treatments. By leveraging their expertise in antibody-based therapies, the company can develop innovative solutions to address unmet medical needs in the field of oncology.

Y-mAbs Therapeutics has the potential to expand its operations and product distribution into emerging markets. By establishing a presence in these regions, the company can tap into the increasing demand for advanced pharmaceutical products, leading to additional revenue streams and market growth.

Threats

Y-mAbs Therapeutics faces several threats that could impact its long-term success:

The pharmaceutical industry operates under strict regulations, requiring companies like Y-mAbs Therapeutics to comply with rigorous standards and obtain necessary approvals. Any failure to meet regulatory requirements may lead to delays in drug development or even the cancellation of projects, negatively impacting the company's financial performance.

Y-mAbs Therapeutics faces intense competition from both established pharmaceutical companies and emerging biotech firms. Competitors may develop similar products or therapeutic alternatives, reducing the market share and pricing power of Y-mAbs Therapeutics. To stay competitive, the company must continue investing in research and development to differentiate its offerings and maintain a leading edge.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Y-mAbs Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Y-mAbs Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Y-mAbs Therapeutics shares outstanding

The number of shares was Y-mAbs Therapeutics in 2024 — This indicates how many shares 43.645 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Y-mAbs Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Y-mAbs Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Y-mAbs Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Y-mAbs Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Y-mAbs Therapeutics.

Y-mAbs Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.16 -0.16  (0.44 %)2024 Q3
6/30/2024-0.13 -0.21  (-56.6 %)2024 Q2
3/31/2024-0.14 -0.15  (-8.3 %)2024 Q1
12/31/2023-0.21 -0.02  (90.24 %)2023 Q4
9/30/2023-0.19 -0.18  (5.56 %)2023 Q3
6/30/2023-0.25 -0.14  (43.2 %)2023 Q2
3/31/2023-0.32 -0.15  (53.83 %)2023 Q1
12/31/2022-0.47 0.03  (106.45 %)2022 Q4
9/30/2022-0.72 -0.63  (13.01 %)2022 Q3
6/30/2022-0.68 -0.94  (-38.46 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Y-mAbs Therapeutics stock

Eulerpool World ESG Rating (EESG©)

30/ 100

🌱 Environment

28

👫 Social

41

🏛️ Governance

21

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees60
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Y-mAbs Therapeutics shareholders

%
Name
Stocks
Change
Date
10.17913 % WG Biotech ApS4,559,233134,00412/31/2023
9.45824 % Paradigm BioCapital Advisors LP4,236,346150,00012/31/2024
7.36280 % HBM Partners AG3,297,800-516,05312/31/2023
6.38943 % Acorn Capital Advisers, LLC2,861,8252,861,82512/31/2024
6.16616 % Acorn Bioventures L.P.2,761,825435,29712/31/2023
6.00303 % BlackRock Institutional Trust Company, N.A.2,688,758-8,74312/31/2024
4.89904 % Sofinnova Investments, Inc2,194,278012/31/2024
4.45019 % The Vanguard Group, Inc.1,993,241-42,12212/31/2024
4.08797 % Polar Capital LLP1,831,000012/31/2024
3.94727 % Caligan Partners, LP1,767,982572,72912/31/2024
1
2
3
4
5
...
10

Y-mAbs Therapeutics Executives and Management Board

Mr. Thomas Gad

(53)
Y-mAbs Therapeutics Vice Chairman of the Board, Chief Business Officer (since 2015)
Compensation 1.44 M

Mr. Bo Kruse

(51)
Y-mAbs Therapeutics Chief Financial Officer, Executive Vice President, Treasurer, Secretary (since 2019)
Compensation 1.15 M

Ms. Susan Smith

(53)
Y-mAbs Therapeutics Senior Vice President, Chief Commercial Officer
Compensation 833,600

Dr. Vignesh Rajah

(58)
Y-mAbs Therapeutics Senior Vice President, Chief Medical Officer
Compensation 724,918

Dr. Steen Lisby

(59)
Y-mAbs Therapeutics Senior Vice President, Chief Scientific Officer
Compensation 712,628
1
2
3

Most common questions regarding Y-mAbs Therapeutics

What values and corporate philosophy does Y-mAbs Therapeutics represent?

Y-mAbs Therapeutics, Inc represents values of dedication, innovation, and patient-centered care. As a biopharmaceutical company, Y-mAbs is committed to developing and commercializing novel antibody-based therapies to address unmet medical needs in pediatric and adolescent patients. Their corporate philosophy emphasizes cutting-edge research, scientific expertise, and a relentless pursuit of improving patients' lives. With a focus on oncology and neuroblastoma, Y-mAbs strives to bring transformative treatments to those in need. Through their dedication to scientific advancements and patient-centric approach, Y-mAbs Therapeutics, Inc aims to make a positive impact on the lives of individuals affected by these diseases.

In which countries and regions is Y-mAbs Therapeutics primarily present?

Y-mAbs Therapeutics, Inc primarily operates in the United States.

What significant milestones has the company Y-mAbs Therapeutics achieved?

Y-mAbs Therapeutics, Inc has achieved several significant milestones. The company obtained accelerated approval from the U.S. FDA for naxitamab in March 2020, for the treatment of high-risk neuroblastoma in pediatric patients aged 1 year and above. Furthermore, Y-mAbs Therapeutics, Inc successfully completed a rolling submission of a Biologics License Application (BLA) in October 2020, seeking full approval for naxitamab, a monoclonal antibody. These achievements highlight the company's commitment to developing innovative therapies for pediatric patients with high-risk neuroblastoma and their dedication to obtaining necessary regulatory approvals. Y-mAbs Therapeutics, Inc's milestones demonstrate their progress in advancing effective medical solutions in the field of oncology.

What is the history and background of the company Y-mAbs Therapeutics?

Y-mAbs Therapeutics, Inc is a biopharmaceutical company specializing in the development and commercialization of innovative antibody-based therapies. Established in 2015, Y-mAbs focuses on developing treatments for pediatric and adult oncology and neuroblastoma. The company's mission is to provide patients with severe diseases access to new and effective treatment options. With a strong emphasis on research and development, Y-mAbs has built a robust pipeline of promising therapies. Led by a team of experienced professionals, Y-mAbs continues to strive for advancements in healthcare and improved patient outcomes. As a leader in the biopharmaceutical industry, Y-mAbs Therapeutics, Inc remains dedicated to making a positive impact on the lives of patients worldwide.

Who are the main competitors of Y-mAbs Therapeutics in the market?

The main competitors of Y-mAbs Therapeutics, Inc in the market include companies such as Novartis AG, Roche Holding AG, AstraZeneca PLC, Pfizer Inc., and Bristol-Myers Squibb Company.

In which industries is Y-mAbs Therapeutics primarily active?

Y-mAbs Therapeutics, Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Y-mAbs Therapeutics?

Y-mAbs Therapeutics, Inc. has a specialized business model focused on developing and commercializing innovative antibody-based therapies. As a clinical-stage biopharmaceutical company, Y-mAbs Therapeutics primarily focuses on discovering, developing, and delivering targeted treatments for pediatric cancers. By harnessing the power of antibodies, Y-mAbs Therapeutics aims to address the unmet medical needs of children with cancer and improve their chances of survival and quality of life. Through strategic partnerships, research, and a patient-centered approach, Y-mAbs Therapeutics aims to revolutionize pediatric oncology and make a significant impact in the field of cancer therapeutics.

What is the P/E ratio of Y-mAbs Therapeutics 2025?

The Y-mAbs Therapeutics P/E ratio is -8.75.

What is the P/S ratio of Y-mAbs Therapeutics 2025?

The Y-mAbs Therapeutics P/S ratio is 2.33.

What is the Quality Investing of Y-mAbs Therapeutics?

The Quality Investing for Y-mAbs Therapeutics is 2/10.

What is the revenue of Y-mAbs Therapeutics 2025?

The expected Y-mAbs Therapeutics revenue is 106.63 M USD.

How high is the profit of Y-mAbs Therapeutics 2025?

The expected Y-mAbs Therapeutics profit is -28.37 M USD.

What is the business model of Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company focused on developing novel cancer drugs specifically targeted to the needs of children and adults with rare, aggressive, and often deadly forms of cancer. The company was founded in 2015 by experienced biotech leaders and has been supported by a variety of private and public financings. Y-mAbs Therapeutics specializes in the development and commercialization of therapeutic antibodies for the treatment of cancer. Their business model focuses on identifying and developing first-in-class or best-in-class therapeutic antibodies that have high efficacy and minimal side effects. The company utilizes advanced technologies and innovative research models to achieve this. Y-mAbs Therapeutics' product pipeline consists of several products in different stages of clinical development. The main antibody in their pipeline is Danyelza (Naxitamab-gqgk), which is used for the treatment of pediatric neuroblastoma. Another antibody in their pipeline is Omburtamab, which is used for the treatment of brain metastases in neuroblastoma patients. In addition to the development of therapeutic antibodies, Y-mAbs Therapeutics also offers diagnostic procedures based on the detection of cancer cell markers. These diagnostic procedures enable early detection of cancer and precise diagnosis of the disease. Y-mAbs Therapeutics' business model strongly focuses on collaboration with other companies and research institutions. The company collaborates with leading clinical facilities and academies to accelerate the development and commercialization of its products. Additionally, the company has entered into several partnerships and licensing agreements with pharmaceutical companies to accelerate the development and commercialization of its products. Y-mAbs Therapeutics aims to expand its global presence. The company plans to market its products in the United States and Europe, seeking approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company plans to market its products in Asia and other regions. In summary, Y-mAbs Therapeutics' business model is based on the development and commercialization of novel cancer drugs targeted to the needs of patients with rare and aggressive forms of cancer. The company utilizes advanced technologies and innovative research models to improve the efficacy and safety of its products. Additionally, the company emphasizes collaboration and partnerships with other companies and research institutions to expand its global presence and accelerate the development and commercialization of its products.

What is the Y-mAbs Therapeutics dividend?

Y-mAbs Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Y-mAbs Therapeutics pay dividends?

The dividend cannot currently be calculated for Y-mAbs Therapeutics or the company does not pay out a dividend.

What is the Y-mAbs Therapeutics ISIN?

The ISIN of Y-mAbs Therapeutics is US9842411095.

What is the Y-mAbs Therapeutics WKN?

The WKN of Y-mAbs Therapeutics is A2N5R0.

What is the Y-mAbs Therapeutics ticker?

The ticker of Y-mAbs Therapeutics is YMAB.

How much dividend does Y-mAbs Therapeutics pay?

Over the past 12 months, Y-mAbs Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Y-mAbs Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Y-mAbs Therapeutics?

The current dividend yield of Y-mAbs Therapeutics is .

When does Y-mAbs Therapeutics pay dividends?

Y-mAbs Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Y-mAbs Therapeutics?

Y-mAbs Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Y-mAbs Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Y-mAbs Therapeutics located?

Y-mAbs Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Y-mAbs Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Y-mAbs Therapeutics from 2/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/26/2025.

When did Y-mAbs Therapeutics pay the last dividend?

The last dividend was paid out on 2/26/2025.

What was the dividend of Y-mAbs Therapeutics in the year 2024?

In the year 2024, Y-mAbs Therapeutics distributed 0 USD as dividends.

In which currency does Y-mAbs Therapeutics pay out the dividend?

The dividends of Y-mAbs Therapeutics are distributed in USD.

All fundamentals about Y-mAbs Therapeutics

Our stock analysis for Y-mAbs Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Y-mAbs Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.